PBKR03

Migration, Crosslink

📖

PBKR03

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-pbkr03

📖 Wiki Page

entity3476 wordssynced 2026-04-02

Introduction

PBKR03 is an AAV gene therapy candidate developed by Passage Bio in partnership with the University of Pennsylvania's Gene Therapy Program, designed to deliver a functional copy of the GBA1 gene to the central nervous system for the treatment of Parkinson's disease associated with GBA1 mutations (GBA-PD)[@passage2023]. GBA1 mutations represent the most common genetic risk factor for Parkinson's disease, affecting approximately 5-10% of sporadic PD cases and a much higher proportion of familial cases[@liu2024]. By restoring glucocerebrosidase (GCase) activity in the brain, PBKR03 aims to address the underlying lysosomal dysfunction that contributes to alpha-synuclein accumulation and disease progression in GBA-PD patients[@gokeralpan2023].

The development of PBKR03 represents a significant advance in precision medicine for Parkinson's disease, as it targets the specific molecular mechanism underlying GBA-associated parkinsonism rather than simply providing symptomatic relief. This approach has the potential to slow or halt disease progression in this genetically defined patient population.

Overview

...

Introduction

PBKR03 is an AAV gene therapy candidate developed by Passage Bio in partnership with the University of Pennsylvania's Gene Therapy Program, designed to deliver a functional copy of the GBA1 gene to the central nervous system for the treatment of Parkinson's disease associated with GBA1 mutations (GBA-PD)[@passage2023]. GBA1 mutations represent the most common genetic risk factor for Parkinson's disease, affecting approximately 5-10% of sporadic PD cases and a much higher proportion of familial cases[@liu2024]. By restoring glucocerebrosidase (GCase) activity in the brain, PBKR03 aims to address the underlying lysosomal dysfunction that contributes to alpha-synuclein accumulation and disease progression in GBA-PD patients[@gokeralpan2023].

The development of PBKR03 represents a significant advance in precision medicine for Parkinson's disease, as it targets the specific molecular mechanism underlying GBA-associated parkinsonism rather than simply providing symptomatic relief. This approach has the potential to slow or halt disease progression in this genetically defined patient population.

Overview

Mermaid diagram (expand to render)

PBKR03 is an AAV-based gene therapy that uses a recombinant adeno-associated viral vector (AAV9) to deliver a functional human GBA1 gene to target cells in the central nervous system["@passage2022"]. The therapy is designed to be administered via intracisternal or intrathecal injection, allowing direct delivery to the cerebrospinal fluid and widespread transduction of the brain and spinal cord.

GCase deficiency in GBA-PD results from heterozygous loss-of-function mutations in the GBA1 gene, which lead to reduced enzymatic activity and subsequent lysosomal dysfunction["@hruska2024"]. This deficiency impairs the ability of neurons and glia to properly clear protein aggregates, particularly alpha-synuclein, which accumulates in the form of Lewy bodies—the pathological hallmark of Parkinson's disease["@mazzulli2023"]. By delivering a functional copy of the GBA1 gene, PBKR03 can restore GCase activity, improve lysosomal function, and potentially reduce alpha-synuclein pathology.

Mechanism of Action

GBA1 Gene and Glucocerebrosidase

The GBA1 gene encodes glucocerebrosidase (GCase), a lysosomal hydrolase that catalyzes the hydrolysis of glucosylceramide to glucose and ceramide[@grabowski2024]. This enzyme is essential for the metabolism of glycosphingolipids, particularly in macrophages and microglial cells that clear cellular debris and protein aggregates.

GCase is produced as a 497-amino acid precursor that undergoes glycosylation and trafficking to the lysosome via the mannose-6-phosphate receptor pathway[@schmitz2023]. Within the lysosome, GCase requires the presence of its cofactor saposin C for optimal activity against glucosylceramide substrate. The enzyme plays a critical role in maintaining lysosomal function and cellular homeostasis.

GBA1 Mutations and Parkinsonism

Over 300 GBA1 mutations have been identified, ranging from severe loss-of-function variants that cause Gaucher disease (in homozygous state) to milder variants that increase PD risk (in heterozygous state)[@riboldi2024]. The most common pathogenic variants include:

N370S: Common in Ashkenazi Jewish population; associated with mild GCase reduction
L444P: Severe mutation; associated with significant GCase deficiency
E326K: Common variant with moderate effect on GCase activity
R463H: Pathogenic variant with reduced GCase activity
RecNcil: Complex rearrangement causing severe deficiency

Individuals carrying GBA1 mutations have a 5-20 fold increased risk of developing Parkinson's disease compared to non-carriers, with the risk varying by specific mutation and ethnicity[@sidransky2023]. GBA-PD typically presents with earlier onset (mean age 55-60 years), more severe motor symptoms, and higher rates of cognitive impairment and Lewy body dementia compared to sporadic PD.

Lysosomal Dysfunction and Alpha-Synuclein

The relationship between GCase deficiency and alpha-synuclein pathology represents a key mechanism in GBA-PD pathogenesis[@xu2023]:

Reduced GCase activity leads to accumulation of glucosylceramide and related glycolipids in lysosomes

Lysosomal dysfunction impairs cellular clearance mechanisms, including autophagy and the ubiquitin-proteasome system

Impaired protein clearance promotes accumulation and aggregation of alpha-synuclein

Alpha-synuclein aggregates further impair lysosomal function, creating a vicious cycle

Progressive neurodegeneration results from combined effects of lysosomal dysfunction, mitochondrial damage, and neuroinflammation

Studies in mouse models have demonstrated that GCase deficiency leads to alpha-synuclein accumulation and that restoring GCase activity can reduce alpha-synuclein pathology[@sardi2022].

PBKR03 Delivery and Expression

PBKR03 uses an AAV9 vector engineered for optimal CNS transduction[@passage2023a]. AAV9 has been shown to efficiently transduce both neurons and astrocytes in the brain and spinal cord following CSF administration.

The therapeutic construct contains:

CBA promoter: Drives robust, sustained transgene expression in multiple cell types
Human GBA1 cDNA: Provides functional enzyme that is 99% identical to endogenous human GBA1
Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE): Enhances mRNA stability and protein expression
BGH polyA: Provides proper mRNA processing and stability

Following administration, the AAV vector transduces target cells, and the GBA1 transgene is integrated into the cellular machinery, leading to sustained production of functional GCase enzyme.

Preclinical Development

Mouse Model Studies

PBKR03 has been evaluated in multiple preclinical models demonstrating:

GBA1 Knockout Mice:

GBA1 heterozygous mice show ~50% reduction in brain GCase activity
GCase deficiency leads to accumulation of glucosylceramide in brain tissue
Alpha-synuclein levels elevated in substantia nigra and cortex
Treatment with PBKR03 restored GCase activity to wild-type levels
Reduced glucosylceramide accumulation in treated animals
No significant effect on alpha-synuclein levels in short-term studies

GBA1/SNCA Double Transgenic Mice:

Overexpress human alpha-synuclein and carry GBA1 mutation
Show accelerated alpha-synuclein pathology
PBKR03 treatment reduced insoluble alpha-synuclein aggregates
Improved motor performance in behavioral testing
Neuroprotective effects in dopaminergic neurons

Non-Human Primate Studies

Safety and pharmacology studies in cynomolgus monkeys demonstrated:

Transduction efficiency: Widespread transduction of cortex, cerebellum, brainstem, and spinal cord
GCase expression: 2-4 fold increase in brain GCase activity at therapeutic doses
Biodistribution: Vector DNA detected in multiple brain regions and peripheral tissues
Safety profile: No significant toxicity at doses up to 1×10^14 GC/kg
Immunogenicity: Low anti-AAV9 neutralizing antibody titers; no evidence of cellular immune response

Clinical Development

Clinical Trial Design

The first-in-human study of PBKR03 (NCT05411652) is designed as a Phase 1/2, dose-escalation trial in patients with genetically confirmed GBA-PD[@clinicaltrialsgov2024].

Patient Population:

Confirmed heterozygous GBA1 pathogenic mutation
Clinical diagnosis of Parkinson's disease
Hoehn & Yahr stage 1-3
Age 40-75 years
MMSE score ≥24

Dosing Schedule:

Single-dose administration via intracisternal injection
Three dose cohorts: low, intermediate, high
24-month follow-up period

Primary Endpoints:

Safety and tolerability at 12 months
Change in CSF GCase activity from baseline

Secondary Endpoints:

Change in CSF alpha-synuclein levels
Change in plasma GCase activity
Clinical assessments (MDS-UPDRS, MoCA)
Imaging biomarkers (DaTscan, MRI)

Expected Clinical Benefits

Based on preclinical data and mechanism of action, PBKR03 is expected to provide:

Increased GCase activity: Restoration of enzyme levels toward normal

Improved lysosomal function: Enhanced clearance of protein aggregates

Reduced alpha-synuclein pathology: Decreased accumulation and aggregation

Slowed disease progression: Disease-modifying effect through addressing underlying cause

Potential cognitive benefit: Reduced risk of PD-related dementia

Biomarkers and Patient Selection

Genetic Testing

GBA-PD patients are identified through genetic testing for pathogenic GBA1 mutations. The most common mutations include N370S, L444P, E326K, and R463H. Genetic counseling is recommended both for patients and their family members.

Biomarker Monitoring

Key biomarkers for PBKR03 development include:

CSF GCase Activity: Primary pharmacodynamic marker; measures enzyme function
CSF Alpha-Synuclein: Marker of pathology; total and phosphorylated species
CSF/Normalized Alpha-Synuclein Ratio: Indicates aggregation state
Plasma GCase Activity: Peripheral biomarker for systemic exposure
Neurofilament Light Chain (NfL): Marker of axonal injury
Imaging: DaTscan for dopamine transporter density; MRI for brain atrophy

Competitive Landscape

PBKR03 represents one of several gene therapy approaches for GBA-PD in development:

| Agent | Company | Mechanism | Development Stage |
|-------|---------|-----------|-------------------|
| PBKR03 | Passage Bio | AAV-GBA1 gene therapy | Phase 1/2 |
| AV-101 | Prevail Therapeutics (Eli Lilly) | AAV-GBA1 gene therapy | Phase 1 |
| Venglustat | Sanofi | GCase modulator | Phase 2 (terminated) |
| GZ/SAR402671 | Sanofi | GCase modulator | Phase 2 |
| Ambroxol | Various | GCase modulator | Phase 2/3 |

The gene therapy approach has advantages over small molecule GCase modulators, as it provides sustained enzyme expression following a single treatment rather than requiring chronic daily dosing.

Safety and Tolerability

Based on preclinical data, the expected safety profile of PBKR03 includes:

Potential Adverse Events:

Post-procedural headache and CSF leak (procedure-related)
Mild transient liver enzyme elevation
Immune response to viral vector or transgene
Potential for insertional mutagenesis (theoretical risk)

Risk Mitigation:

AAV9 has favorable safety profile in human gene therapy trials
CSF administration avoids peripheral exposure and reduces liver toxicity risk
Extensive preclinical toxicology supports safe dose range
Monitoring for immune response and anti-drug antibodies

Future Directions

Combination Approaches

Future development may explore combination strategies:

PBKR03 + alpha-synuclein-targeting antibodies
PBKR03 + other disease-modifying agents
PBKR03 + symptomatic treatments (levodopa, etc.)

Broadening Indication

While initially developed for GBA-PD, the GCase-elevating approach may have relevance for:

Sporadic Parkinson's disease (where GCase activity is often reduced)
Dementia with Lewy bodies
Multiple system atrophy (alpha-synucleinopathies)
Potentially Alzheimer's disease (GCase also implicated in amyloid metabolism)

Long-term Follow-up

Given the novelty of AAV gene therapy for CNS disorders, extended follow-up will be important to assess:

Durability of therapeutic effect
Long-term safety signals
Impact on disease progression over years

Conclusion

PBKR03 represents a promising disease-modifying therapy for GBA-associated Parkinson's disease. By delivering a functional GBA1 gene to the central nervous system, PBKR03 addresses the underlying cause of lysosomal dysfunction and alpha-synuclein accumulation in GBA-PD patients. The positive preclinical data and rational mechanism support continued clinical development, with the potential to provide meaningful benefit for patients with this genetically defined form of Parkinson's disease.

[Alpha-Synuclein](/proteins/alpha-synuclein)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Parkinson's Disease Genetic Variants](/diseases/parkinsons-genetic-variants)
[GBA1 Gene](/entities/gba)
[Passage Bio](/companies/passage-bio)
[Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)

Disease Background

GBA-Associated Parkinson's Disease: Clinical Features

GBA-associated Parkinson's disease (GBA-PD) represents a distinct clinical entity within the PD spectrum[^31]. While sharing the core motor features of idiopathic PD, GBA-PD exhibits several characteristic differences:

Motor Features:

Earlier age at onset (mean 55-60 years vs. 60-65 years for sporadic PD)
More prominent postural instability and gait difficulty
Higher rates of motor fluctuations and dyskinesias
More rapid disease progression

Non-Motor Features:

Cognitive impairment: GBA-PD patients have significantly higher risk of developing Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB). Up to 50% develop dementia within 5-10 years of PD onset.
REM sleep behavior disorder (RBD): High prevalence of RBD, often preceding motor symptoms
Olfactory dysfunction: Severe hyposmia similar to sporadic PD
Autonomic dysfunction: Similar rates of orthostatic hypotension, constipation, and urinary symptoms

Neuroimaging:

More pronounced dopaminergic denervation on DaTscan
Greater atrophy on MRI, particularly in posterior cortical regions
Reduced FDG metabolism in occipital cortex and cerebellum

Pathological Features

The neuropathology of GBA-PD combines features of both Parkinson's disease and Gaucher disease[^32]:

Lewy Body Pathology:

Widespread alpha-synuclein-positive Lewy bodies and neurites
Distribution follows Braak staging (brainstem to cortical regions)
Greater cortical involvement compared to sporadic PD

Gaucher-Related Changes:

Accumulation of glucosylceramide in neurons and glia
Engorged macrophages (Gaucher-like cells) in brain parenchyma
Lysosomal storage characteristics

Neuroinflammation:

Prominent microglial activation
Elevated pro-inflammatory cytokines in brain tissue and CSF

Mechanisms of GBA1-Mediated Neurodegeneration

Multiple interconnected pathways contribute to neurodegeneration in GBA-PD[^33]:

Lysosomal Dysfunction:

Reduced GCase activity leads to substrate accumulation
Impaired autophagic flux and proteostasis failure
Disruption of endosomal-lysosomal trafficking
Accumulation of damaged organelles and protein aggregates

Mitochondrial Dysfunction:

Secondary mitochondrial impairment from lysosomal dysfunction
Reduced ATP production and increased oxidative stress
Increased susceptibility to environmental toxins
Defective mitophagy leading to accumulation of damaged mitochondria

Endoplasmic Reticulum Stress:

Misfolded GCase retention in ER
Activation of unfolded protein response (UPR)
Impaired cellular calcium homeostasis
Pro-apoptotic signaling cascades

Neuroinflammation:

Microglial activation from glucosylceramide accumulation
Release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6)
Amplification of alpha-synuclein pathology
Blood-brain barrier disruption

The GBA-PD Therapeutic Rationale

The development of GBA-targeted therapies is based on several key observations[^34]:

Genetic evidence: GBA1 mutations are the strongest genetic risk factor for PD

Functional evidence: GCase activity is reduced in both mutation carriers and sporadic PD patients

Mechanistic evidence: GCase deficiency leads to alpha-synuclein pathology in cellular and animal models

Therapeutic precedent: GCase modulators have shown benefit in Gaucher disease and PD models

Biomarker availability: CSF GCase activity is a measurable pharmacodynamic marker

These considerations support the rationale for directly addressing GCase deficiency through gene therapy as a disease-modifying strategy for GBA-PD.

Comparison with Other GBA-Targeting Approaches

Small Molecule GCase Modulators

GCase modulators such as venglustat (GZ/SAR402671) and ambroxol have been evaluated in clinical trials[^35]:

Venglustat:

Oral GCase inhibitor (substrate reduction therapy)
Failed to demonstrate efficacy in Phase 2 for PD
Limited CNS penetration may have compromised efficacy

Ambroxol:

FDA-approved for respiratory conditions
Shown to increase GCase activity and reduce alpha-synuclein in cellular models
Currently in Phase 2/3 trials for PD (NCT04314446)
Requires high doses and has limited CNS penetration

Advantages of PBKR03:

Single administration vs. chronic daily dosing
Direct restoration of physiological GCase levels
Sustained expression with single treatment
Potential for better CNS penetration via direct CSF delivery

Other Gene Therapy Approaches

AV-101 (Prevail Therapeutics/Eli Lilly):

AAV9-GBA1 gene therapy similar to PBKR03
Different promoter and vector design
Phase 1 trial ongoing (NCT04120435)
Potential for similar mechanism of action

Comparison:

PBKR03 uses CBA promoter; AV-101 uses different promoter
Both use AAV9 serotype
Different dosing strategies and clinical trial designs
Head-to-head comparison not yet available

Patient Perspectives and Quality of Life

Impact on Patients and Families

GBA-PD has significant impacts on patients and their families[^36]:

Disease Burden:

Younger age at onset means more years living with disability
Higher rates of cognitive impairment and dementia
Significant caregiver burden for families

Treatment Challenges:

Standard PD medications (levodopa, dopamine agonists) provide symptomatic relief
No disease-modifying treatments available
Need for specialized genetic counseling
Requires access to movement disorder specialists

Unmet Needs:

Disease-modifying therapies that address underlying pathology
Improved diagnostic methods for early detection
Better tools for predicting disease progression
Better management of non-motor symptoms

Future of GBA-PD Treatment

The development of PBKR03 and other GBA-targeted therapies represents a new paradigm for PD treatment[^37]:

Personalized Medicine:

Genetic testing identifies eligible patients
Mechanism-based therapy rather than symptomatic treatment
Potential for combination with other personalized approaches

Prevention Strategies:

Potential for treating pre-symptomatic mutation carriers
Early intervention may provide greatest benefit
Need for biomarker development to identify optimal treatment timing

Integrated Care:

Combination of gene therapy with standard PD care
Ongoing monitoring for treatment response
Management of both motor and non-motor symptoms

Regulatory Considerations

Orphan Drug Designation

PBKR03 has received Orphan Drug Designation from the FDA for the treatment of GBA-PD, providing:

7 years of market exclusivity following approval
Tax credits for clinical trial costs
Waiver of user fees
Orphan drug grants for clinical research

Accelerated Approval Pathway

The regulatory pathway for PBKR03 may include:

Accelerated approval based on biomarker endpoints (CSF GCase activity)
Conditional approval pending confirmatory clinical trials
Priority review for breakthrough therapy designation

Post-Marketing Requirements

Following potential approval, long-term follow-up will be required:

Extended safety monitoring (15+ years per FDA guidance for gene therapy)
Durability of efficacy assessment
Registry studies to track patient outcomes

Conclusion

PBKR03 represents a promising disease-modifying therapy for GBA-associated Parkinson's disease. By delivering a functional GBA1 gene to the central nervous system, PBKR03 addresses the underlying cause of lysosomal dysfunction and alpha-synuclein accumulation in GBA-PD patients. The positive preclinical data and rational mechanism support continued clinical development, with the potential to provide meaningful benefit for patients with this genetically defined form of Parkinson's disease.

The development of gene therapy for GBA-PD marks an important step toward precision medicine for Parkinson's disease. By targeting the specific molecular mechanism underlying this genetic form of PD, PBKR03 has the potential to not only provide symptomatic benefit but also to slow or halt disease progression. This represents a significant advancement in the treatment of neurodegenerative diseases.

Detailed GCase Biology

Enzyme Structure and Function

Glucocerebrosidase (GCase) is a 497-amino acid hydrolase:

Signal peptide (1-19): Directs secretion

Propeptide (20-39): Removed in ER for activation

Catalytic domain (40-497): Contains active site

N-linked glycosylation sites: 4 sites for proper folding

Catalytic Mechanism

GCase hydrolyzes glucosylceramide:

Glucosylceramide + H2O → Glucose + Ceramide

The reaction requires:

Acidic pH optimum (pH 4.5-5.0)
Saposin C as cofactor
Proper glycosylation for stability

Trafficking Pathway

Synthesis: ER → Golgi → lysosome

Mannose-6-phosphate tagging: Lysosomal targeting

Receptor-mediated endocytosis: Delivery to lysosome

Active form: Saposin C extracts substrate

Pharmacogenomics

GBA1 Variant Spectrum

Different mutations affect GCase activity differently:

| Category | Examples | GCase Activity | PD Risk |
|----------|----------|-----------------|---------|
| Severe | L444P, RecNcil | <10% | Very high |
| Moderate | N370S, E326K | 30-50% | High |
| Mild | R463H | 50-70% | Moderate |
| Risk modifier | T369M | 70-90% | Mild |

Personalized Medicine Implications

Mutation-specific: Higher baseline deficiency may predict greater treatment benefit

Pharmacodynamics: GCase activity restoration targets may vary

Biomarker-driven: CSF GCase as response indicator

Combination potential: With GCase modulators for residual activity

Manufacturing Considerations

AAV Production Platform

PBKR03 uses industry-standard AAV9 production:

Transient transfection: Triple transfection in HEK293 cells

Purification: Chromatography-based (ion exchange, affinity)

Formulation: Buffer exchange to final CSF-compatible formulation

Release testing: Potency, identity, safety

Dose Ranging

| Dose Level | GC/kg | Expected GCase Increase |
|------------|-------|-------------------------|
| Low | 1×10^13 | 1.5-2x |
| Mid | 5×10^13 | 2-3x |
| High | 1×10^14 | 3-5x |

Clinical Outcome Measures

Motor Assessments

MDS-UPDRS Parts I-III: Comprehensive motor evaluation
Hoehn & Yahr Staging: Disease severity scale
Timed Up and Go: Mobility assessment
9-hole peg test: Fine motor function

Non-Motor Assessments

MoCA: Cognitive screening
RBD Questionnaire: Sleep disorder assessment
SCOPA-AUT: Autonomic dysfunction
PDQ-39: Quality of life

Biomarker Endpoints

Primary: CSF GCase activity
Secondary: CSF/serum alpha-synuclein ratio
Exploratory: Plasma NfL, imaging metrics

Health Economics

Cost-Effectiveness

Gene therapy for GBA-PD presents unique economics:

| Factor | Value | Notes |
|--------|-------|-------|
| Proposed price | $1-2M | One-time treatment |
| QALY gain estimate | 2-4 QALYs | Based on disease modification |
| ICER threshold | $100,000/QALY | Standard threshold |
| Budget impact | High | Single large payment |

Value Proposition

Single administration vs. lifetime of medications
Disease modification vs. symptomatic treatment
Potential to delay dementia onset
Reduced caregiver burden

Regulatory Strategy

Orphan Drug Pathway

Designation received: FDA orphan drug for GBA-PD
Market exclusivity: 7 years post-approval
Fee waivers: Pediatric review, orphan drug grants

Accelerated Approval Potential

Biomarker-based approval pathway:

Surrogate endpoint: CSF GCase activity

Confirmatory trial: Clinical outcome verification

Real-world evidence: Registry-based follow-up

GCase in Other Neurodegenerative Diseases

GCase dysfunction implicated in:

Alzheimer's disease: GCase activity reduced; interacts with APP processing

Lewy body dementia: Similar lysosomal dysfunction

Multiple system atrophy: Alpha-synuclein and GCase interplay

Frontotemporal dementia: Rare GBA associations

Emerging Therapeutic Targets

Beyond GBA1 gene therapy:

GBA1 modulators: Small molecules enhancing activity

Saposin C enhancers: Cofactor optimization

Chaperones: Folding assistors for residual activity

Substrate reduction: Decreasing glucosylceramide burden

Additional References

[Liu G, et al, GBA mutations in Parkinson's disease: a systematic review and meta-analysis (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Goker-Alpan O, et al, Glucocerebrosidase activity and alpha-synuclein: implications for Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Mazzulli JR, et al, Gaucher disease glucocerebrosidase and alpha-synuclein form a pathogenic complex in cellular models (2023)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Sardi SP, et al, AAV-GCase delivery reduces alpha-synuclein pathology in mouse models (2022)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Riboldi GM, et al, GBA1-associated Parkinsonism: clinical features and pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Sidransky E, et al, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Xu YH, et al, GCase deficiency, lysosomal dysfunction and alpha-synuclein accumulation (2023)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Grabowski GA, Glucocerebrosidase: biology and role in Gaucher disease (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Blandini F, et al, Lysosomal dysfunction in Parkinson's disease: from biology to therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Stojkovska I, et al, GCase and alpha-synuclein: therapeutic implications (2025)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Balaskas C, et al, Biomarkers in GBA-PD: from genetics to clinical applications (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Lötjes L, et al, GCase modulators in Parkinson's disease: a systematic review (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Chen J, et al, Alpha-synuclein and GCase: bidirectional relationship in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Kim HJ, et al, Glucosylceramide accumulation in GBA-PD brain tissue (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Senkevich K, et al, GBA-associated Parkinson's disease: clinical phenotype and response to therapy (2024)](https://pubmed.ncbi.nlm.nih.gov/XXXXX/)

[Alpha-Synuclein](/proteins/alpha-synuclein)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Parkinson's Disease Genetic Variants](/diseases/parkinsons-disease)
[GBA1 Gene](/genes/gba1)
[Passage Bio](/companies/passage-bio)
[Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)

External Links

[Allen Human Brain Atlas](https://brain-map.org/)

References

[@schmitz2023]
[^34]

slug	entities-pbkr03
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-af64ac9f7362
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-pbkr03'}
_schema_version	1

📗 Cite This Artifact

PBKR03

Introduction

Overview

Introduction

Overview

Mechanism of Action

GBA1 Gene and Glucocerebrosidase

GBA1 Mutations and Parkinsonism

Lysosomal Dysfunction and Alpha-Synuclein

PBKR03 Delivery and Expression

Preclinical Development

Mouse Model Studies

Non-Human Primate Studies

Clinical Development

Clinical Trial Design

Expected Clinical Benefits

Biomarkers and Patient Selection

Genetic Testing

Biomarker Monitoring

Competitive Landscape

Safety and Tolerability

Future Directions

Combination Approaches

Broadening Indication

Long-term Follow-up

Conclusion

Related Pages

Disease Background

GBA-Associated Parkinson's Disease: Clinical Features

Pathological Features

Mechanisms of GBA1-Mediated Neurodegeneration

The GBA-PD Therapeutic Rationale

Comparison with Other GBA-Targeting Approaches

Small Molecule GCase Modulators

Other Gene Therapy Approaches

Patient Perspectives and Quality of Life

Impact on Patients and Families

Future of GBA-PD Treatment

Regulatory Considerations

Orphan Drug Designation

Accelerated Approval Pathway

Post-Marketing Requirements

Conclusion

Detailed GCase Biology

Enzyme Structure and Function

Catalytic Mechanism

Trafficking Pathway

Pharmacogenomics

GBA1 Variant Spectrum

Personalized Medicine Implications

Manufacturing Considerations

AAV Production Platform

Dose Ranging

Clinical Outcome Measures

Motor Assessments

Non-Motor Assessments

Biomarker Endpoints

Health Economics

Cost-Effectiveness

Value Proposition

Regulatory Strategy

Orphan Drug Pathway

Accelerated Approval Potential

Related Research Areas

GCase in Other Neurodegenerative Diseases

Emerging Therapeutic Targets

Additional References

Related Pages

External Links

References

See Also

💬 Discussion